Financial statements are reported in CNY and shown here converted to USD at today's exchange rate.
BNR — Burning Rock Biotech Limited
$13.29
$-0.04 (-0.30%)
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Market Cap
$140.16M
Forward P/E
-22.9x
52-Week Range
N/A
BNR Price History
Revenue vs. Net Income
$84.4M
Revenue · FY2022
Annual. Net margin is shown under each year.
Free Cash Flow
-$79M
FCF · FY2022
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-83.4%
ROCE · FY2022
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.7x
Assets ÷ liabilities · FY2022
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
12.5%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
10.4M
Diluted shares · FY2022
Only one year of share data is available, so no change can be shown yet.
